Related Experiment Video
Updated: Jan 6, 2026
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients
Ilhan Tahrali1, Umut Can Kucuksezer1, Nilgun Akdeniz1
1Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology, Istanbul, Turkey.
Abstract:
Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.
Insights
Interferon-beta (IFN-β) therapy for relapsing-remitting Multiple Sclerosis (RR-MS) may increase Natural Killer (NK) cell pro-inflammatory activity. This study found elevated activating receptors and Interleukin-22 (IL-22) in RR-MS patients on IFN-β.
Area of Science:
- Immunology
- Neuroimmunology
- Cellular Biology
Background:
- Multiple Sclerosis (MS) is a central nervous system disease involving immune-mediated and neurodegenerative processes.
- Relapsing-remitting MS (RR-MS) is the most common form, characterized by acute attacks and remissions.
- First-line treatments for RR-MS include interferon-beta (IFN-β) and glatiramer acetate.
Purpose of the Study:
- To investigate the expression of activating and inhibitory receptors on Natural Killer (NK) cells.
- To measure Interleukin-22 (IL-22) levels in RR-MS patients.
- To compare NK cell profiles in RR-MS patients with and without IFN-β therapy.
Main Methods:
- Flow cytometry was used to analyze NK cell receptor expression.
- Interleukin-22 (IL-22) levels were quantified.
- NK cell analysis was performed on RR-MS patients undergoing IFN-β treatment and those not receiving it.
Main Results:
- NK cells from RR-MS patients on IFN-β therapy showed increased expression of activating receptors.
- Interleukin-22 (IL-22) levels were elevated in RR-MS patients undergoing IFN-β treatment.
- These findings suggest a shift towards a pro-inflammatory NK cell phenotype with IFN-β therapy.
Conclusions:
- IFN-β therapy in RR-MS patients is associated with enhanced NK cell activating profiles.
- Elevated IL-22 levels in conjunction with increased NK cell activation suggest a pro-inflammatory role.
- IFN-β may modulate NK cells towards a pro-inflammatory state in RR-MS treatment.
More Related Videos
10:58Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry
Published on: March 5, 2019
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
